This is the authors' abstract. We don't add key points for this paper.
Mesenchymal stem or progenitor cells remain the cells of choice for many regenerative treatment strategies in orthopedics. Due to a number of reasons such as regulatory burdens, time- and cost-efficiency and patient safety, bone-marrow-aspirate-concentrate (BMAC) has become an increasingly important source for application of mesenchymal stem cells (MSCs). However, specific surgical application techniques, as well as treatment regimes, often remain poorly discussed in the literature. This article aims to bridge this gap by providing comprehensive information for practicing surgeons to ease patient selection and clinical application of BMAC for chondral defects.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Neubauer et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: